{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:08:17Z","timestamp":1793678897187,"version":"4.5.1"},"reference-count":174,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cholangiocarcinoma is characterized by a poor prognosis with limited treatment and management options. Chemotherapy using gemcitabine with cisplatin is the only available first-line therapy for patients with advanced cholangiocarcinoma, although it offers only palliation and yields a median survival of &amp;lt; 1 year. Recently there has been a resurgence of immunotherapy studies focusing on the ability of immunotherapy to inhibit cancer growth by impacting the tumor microenvironment. Based on the TOPAZ-1 trial, the US Food and Drug Administration has approved the combination of durvalumab and gemcitabine with cisplatin as the first-line treatment of cholangiocarcinoma. However, immunotherapy, like immune checkpoint blockade, is less effective in cholangiocarcinoma than in other types of cancer. Although several factors such as the exuberant desmoplastic reaction are responsible for cholangiocarcinoma treatment resistance, existing literature on cholangiocarcinoma cites the inflammatory and immunosuppressive environment as the most common factor. However, mechanisms activating the immunosuppressive tumor microenvironment contributing to cholangiocarcinoma drug resistance are complicated. Therefore, gaining insight into the interplay between immune cells and cholangiocarcinoma cells, as well as the natural development and evolution of the immune tumor microenvironment, would provide targets for therapeutic intervention and improve therapeutic efficacy by developing multimodal and multiagent immunotherapeutic approaches of cholangiocarcinoma to overcome the immunosuppressive tumor microenvironment. In this review, we discuss the role of the inflammatory microenvironment-cholangiocarcinoma crosstalk and reinforce the importance of inflammatory cells in the tumor microenvironment, thereby highlighting the explanatory and therapeutic shortcomings of immunotherapy monotherapy and proposing potentially promising combinational immunotherapeutic strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1037945","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T05:54:46Z","timestamp":1681710886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies"],"prefix":"10.3389","volume":"14","author":[{"given":"Xianzhe","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31278","article-title":"Molecular targets in cholangiocarcinoma","volume":"1","author":"O'Rourke","year":"2020","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination cancer immunotherapies tailored to the tumour microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.09.004","article-title":"Rational development of combination therapies for biliary tract cancers","volume":"78","author":"Harding","year":"2023","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/liv.14098","article-title":"The tumour microenvironment and immune milieu of cholangiocarcinoma","author":"Fabris","year":"2019","journal-title":"Liver Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32343","article-title":"Beyond the tumour microenvironment","volume":"145","author":"Laplane","year":"2019","journal-title":"Int J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0715","article-title":"PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma","volume":"22","author":"Sabbatino","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0037","article-title":"Toward precision radiotherapy for use with immune checkpoint blockers","volume":"24","author":"Vanpouille-Box","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3390\/cancers11111706","article-title":"Recreating tumour complexity in a dish: Organoid models to study liver cancer cells and their extracellular environment","volume":"11","author":"van Tienderen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.012","article-title":"Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages","volume":"66","author":"Raggi","year":"2017","journal-title":"J Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.941289","article-title":"Exploring the function of stromal cells in cholangiocarcinoma by three-dimensional bioprinting immune microenvironment model","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2017.07.028","article-title":"The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma","volume":"1864","author":"Cadamuro","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaut.2019.03.007","article-title":"The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine","volume":"100","author":"Rimassa","year":"2019","journal-title":"J Autoimm"},{"key":"B19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nri.2017.76","article-title":"Single-cell RNA sequencing to explore immune cell heterogeneity","volume":"18","author":"Papalexi","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12967-022-03424-5","article-title":"Single-cell landscape of immunocytes in patients with extrahepatic cholangiocarcinoma","volume":"20","author":"Xu","year":"2022","journal-title":"J Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.029","article-title":"Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling","volume":"77","author":"Rosenberg","year":"2022","journal-title":"J Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.008","article-title":"The immune revolution: A case for priming, not checkpoint","volume":"33","author":"Vonderheide","year":"2018","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0747-y","article-title":"Tumors induce the formation of suppressor endothelial cells in vivo","volume":"59","author":"Mulligan","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.05.002","article-title":"The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO","volume":"35","author":"Mondanelli","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/imr.12464","article-title":"Innate immune mediators in cancer: between defense and resistance","volume":"274","author":"Berraondo","year":"2016","journal-title":"Immunol Rev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.canlet.2019.05.019","article-title":"Individualized precision treatment: Targeting TAM in HCC","volume":"458","author":"Li","year":"2019","journal-title":"Cancer Lett"},{"key":"B27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13075-017-1310-4","article-title":"M2 macrophage is the predominant phenotype in airways inflammatory lesions in patients with granulomatosis with polyangiitis","volume":"19","author":"de Souza","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01614.x","article-title":"Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma","volume":"101","author":"Hasita","year":"2010","journal-title":"Cancer Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.29514","article-title":"M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3\/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma","volume":"121","author":"Sun","year":"2020","journal-title":"J Cell Biochem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2015.16.7.3043","article-title":"Quantitative changes in tumor-associated M2 macrophages characterize cholangiocarcinoma and their association with metastasis","volume":"16","author":"Thanee","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000613","article-title":"Immune contexture of cholangiocarcinoma","volume":"36","author":"Paillet","year":"2020","journal-title":"Curr Opin Gastroenterol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76452","article-title":"WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited","volume":"125","author":"Boulter","year":"2015","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-1698-2","article-title":"Activated macrophages promote wnt\/beta-catenin signaling in cholangiocarcinoma cells","volume":"35","author":"Loilome","year":"2014","journal-title":"Tumour Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.01.007","article-title":"Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma","volume":"4","author":"H\u00f8gdall","year":"2018","journal-title":"Trends Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"103375","DOI":"10.1016\/j.ebiom.2021.103375","article-title":"Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target","volume":"67","author":"Zhou","year":"2021","journal-title":"EBioMedicine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24249","article-title":"Prognostic significance of TIE2-expressing monocytes in hilar cholangiocarcinoma","volume":"114","author":"Atanasov","year":"2016","journal-title":"J Surg Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/bst.2019.01003","article-title":"Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications","volume":"13","author":"Yu","year":"2019","journal-title":"Biosci Trends"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.967982","article-title":"Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma","volume":"12","author":"Xu","year":"2022","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci Transl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617903113","article-title":"The innate immune receptor dectin-2 mediates the phagocytosis of cancer cells by kupffer cells for the suppression of liver metastasis","volume":"113","author":"Kimura","year":"2016","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B42","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ccell.2017.05.006","article-title":"Kupffer cell-derived tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS","volume":"31","author":"Yuan","year":"2017","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/62759","article-title":"Kupffer cells in immune activation and tolerance toward HBV\/HCV infection","volume":"26","author":"Yuan","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-022-01253-z","article-title":"Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses","volume":"15","author":"Xia","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27840","article-title":"The biliary epithelium presents antigens to and activates natural killer T cells","volume":"62","author":"Schrumpf","year":"2015","journal-title":"Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14267","article-title":"Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma","volume":"111","author":"Fukuda","year":"2020","journal-title":"Cancer Sci"},{"key":"B47","article-title":"Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro","volume":"32","author":"Morisaki","year":"2012","journal-title":"Anticancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3390\/ijms19102885","article-title":"The role of stroma in cholangiocarcinoma: The intriguing interplay between fibroblastic component, immune cell subsets and tumor epithelium","volume":"19","author":"Gentilini","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11307","article-title":"In vivo study of natural killer (NK) cell cytotoxicity against cholangiocarcinoma in a nude mouse model","volume":"32","author":"Jung","year":"2018","journal-title":"In Vivo"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.3390\/ijms21103726","article-title":"Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer","volume":"21","author":"Sordo-Bahamonde","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2015.05.050","article-title":"The immunoregulatory effects of Chinese herbal medicine on the maturation and function of dendritic cells","volume":"171","author":"Li","year":"2015","journal-title":"J Ethnopharmacol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.037","article-title":"CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma","volume":"74","author":"Diggs","year":"2021","journal-title":"J Hepatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.coi.2017.01.002","article-title":"Dendritic cells in cancer: the role revisited","volume":"45","author":"Veglia","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-016-0592-y","article-title":"The role of dendritic cells in cancer","volume":"39","author":"Hansen","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2013.38","article-title":"Inactivation of tumor-specific CD8(+) CTLs by tumor-infiltrating tolerogenic dendritic cells","volume":"91","author":"Harimoto","year":"2013","journal-title":"Immunol Cel Biol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2004.03.016","article-title":"Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma","volume":"35","author":"Takagi","year":"2004","journal-title":"Hum Pathol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1865308","article-title":"Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy","volume":"30","author":"Wang","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1701913","article-title":"Suppression of TGF-\u03b2 and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells","volume":"16","author":"Thepmalee","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2212-2","article-title":"Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells","volume":"67","author":"Panya","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21777","article-title":"Functional impairment of circulating FcepsilonRI(+) monocytes and myeloid dendritic cells in hepatocellular carcinoma and cholangiocarcinoma patients","volume":"96","author":"Martin-Sierra","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02746-x","article-title":"Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40\/CD40L on dendritic cells","volume":"70","author":"Sadeghlar","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2583","article-title":"Tumor-associated neutrophils: new targets for cancer therapy","volume":"71","author":"Gregory","year":"2011","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \"N1\" versus \"N2\" TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B65","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/carcin\/bgt397","article-title":"CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils","volume":"35","author":"Zhou","year":"2014","journal-title":"Carcinogenesis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.401","article-title":"Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma","volume":"118","author":"Kitano","year":"2018","journal-title":"Br J Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2268-8","article-title":"Intratumoral IL-17(+) cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma","volume":"19","author":"Gu","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i16.4961","article-title":"Prognostic value of neutrophil distribution in cholangiocarcinoma","volume":"21","author":"Mao","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"32","DOI":"10.20892\/j.issn.2095-3941.2019.0372","article-title":"Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment","volume":"17","author":"Zhang","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgs123","article-title":"Tumor-associated neutrophils: friend or foe","volume":"33","author":"Fridlender","year":"2012","journal-title":"Carcinogenesis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-38862-1_4","article-title":"Adaptive immunity and the tumor microenvironment","volume":"180","author":"Han","year":"2020","journal-title":"Cancer Res Treat"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13087","article-title":"Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma","volume":"49","author":"Tamma","year":"2019","journal-title":"Eur J Clin Invest"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21376","article-title":"Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion","volume":"100","author":"Ye","year":"2009","journal-title":"J Surg Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.610","article-title":"Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer","volume":"109","author":"Goeppert","year":"2013","journal-title":"Br J Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.416","article-title":"Immune infiltration in human tumors: a prognostic factor that should not be ignored","volume":"29","author":"Pages","year":"2010","journal-title":"Oncogene"},{"key":"B76","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13046-022-02340-2","article-title":"The role of tumor-infiltrating lymphocytes in cholangiocarcinoma","volume":"41","author":"Liu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-020-01967-y","article-title":"Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma","volume":"21","author":"Asahi","year":"2020","journal-title":"Surg Today"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S172719","article-title":"Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8(+) T-cell immune responses","volume":"10","author":"Zhu","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12957-020-02082-5","article-title":"PD-1\/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome","volume":"18","author":"Tian","year":"2020","journal-title":"World J Surg Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.73949","article-title":"Tumor microenvironment and its implications for antitumor immunity in cholangiocarcinoma: Future perspectives for novel therapies","volume":"18","author":"Cao","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B81","doi-asserted-by":"publisher","first-page":"14419","DOI":"10.1038\/s41598-017-14838-3","article-title":"Activation of Fas\/FasL pathway and the role of c-FLIP in primary culture of human cholangiocarcinoma cells","volume":"7","author":"Carnevale","year":"2017","journal-title":"Sci Rep"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.5053","article-title":"Liver tumor infiltrating lymphocytes: comparison of hepatocellular and cholangiolar carcinoma","volume":"15","author":"Kasper","year":"2009","journal-title":"World J Gastroenterol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.05.026","article-title":"Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules","volume":"71","author":"Zhou","year":"2019","journal-title":"J Hepatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/1348-0421.12500","article-title":"Large Numbers of interleukins-22- and -17A-producing T helper cells in cholangiocarcinoma related to liver fluke infection","volume":"61","author":"Su","year":"2017","journal-title":"Microbiol Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.MR0318-097R","article-title":"T Lymphocyte subsets in cancer immunity: Friends or foes","volume":"105","author":"Chraa","year":"2019","journal-title":"J Leukoc Biol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.118","article-title":"TH2 cell development and function","volume":"18","author":"Walker","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-019-01146-9","article-title":"T Helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer","volume":"42","author":"Chang","year":"2019","journal-title":"Arch Pharmacol Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402669","article-title":"Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics","volume":"194","author":"Zanetti","year":"2015","journal-title":"J Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/ni1455","article-title":"Foxp3 in control of the regulatory T cell lineage","volume":"8","author":"Zheng","year":"2007","journal-title":"Nat Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.01.067","article-title":"Downregulation of FOXP3 inhibits invasion and immune escape in cholangiocarcinoma","volume":"458","author":"Ma","year":"2015","journal-title":"Biochem Biophys Res Comm"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29296","article-title":"aPKC-iota\/P-Sp1\/Snail signaling induces epithelial-mesenchymal transition and immunosuppression in cholangiocarcinoma","volume":"66","author":"Qian","year":"2017","journal-title":"Hepatology"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.027","article-title":"Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient","volume":"65","author":"Loffler","year":"2016","journal-title":"J Hepatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-011-0437-y","article-title":"Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma","volume":"19","author":"Shimizu","year":"2012","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"B95","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-019-0501-8","article-title":"Allogenic Vgamma9Vdelta2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma","volume":"7","author":"Alnaggar","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13885","article-title":"Immune responses against tumour-associated antigen-derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients","volume":"38","author":"Kida","year":"2018","journal-title":"Liver Int"},{"key":"B98","article-title":"MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer","volume":"25","author":"Yamamoto","year":"2005","journal-title":"Anticancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2011.424","article-title":"Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis","volume":"3","author":"Yoshitomi","year":"2012","journal-title":"Exp Ther Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1010428317733367","DOI":"10.1177\/1010428317733367","article-title":"Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA","volume":"39","author":"Junking","year":"2017","journal-title":"Tumour Biol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.29.5.1319","article-title":"Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma","volume":"29","author":"Zhu","year":"2006","journal-title":"Int J Oncol"},{"key":"B102","article-title":"Overexpression of adenovirus-mediated p27kip1 lacking the Jab1-binding region enhances cytotoxicity and inhibits xenografted human cholangiocarcinoma growth","volume":"29","author":"Shiraso","year":"2009","journal-title":"Anticancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.3390\/cancers11111667","article-title":"A cancer-favoring, engineered vaccinia virus for cholangiocarcinoma","volume":"11","author":"Yoo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2012.136","article-title":"A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma","volume":"24","author":"Lange","year":"2013","journal-title":"Hum Gene Ther"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3294","article-title":"Dual-modality imaging demonstrates the enhanced antitumoral effect of herpes simplex virus-thymidine kinase\/ganciclovir plus gemcitabine combination therapy on cholangiocarcinoma","volume":"12","author":"Wang","year":"2016","journal-title":"Exp Ther Med"},{"key":"B106","article-title":"Combined treatment of cholangiocarcinoma with interventional radiofrequency hyperthermia and heat shock protein promoter-mediated HSV-TK gene therapy","volume":"8","author":"Luo","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","first-page":"iv112","DOI":"10.1093\/annonc\/mdz156.008","article-title":"Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC","author":"Kaseb","year":"2019","journal-title":"Ann Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"B110","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-021-01342-6","article-title":"Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development","volume":"20","author":"Huang","year":"2021","journal-title":"Mol Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40779-022-00399-8","article-title":"mRNA vaccine development for cholangiocarcinoma: a precise pipeline","volume":"9","author":"Tang","year":"2022","journal-title":"Mil Med Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1359362","article-title":"Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers","volume":"13","author":"Hochnadel","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181fb65b9","article-title":"Phase 1 trial of wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer","volume":"34","author":"Kaida","year":"2011","journal-title":"J Immunother"},{"key":"B114","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s40425-018-0446-3","article-title":"Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients","volume":"6","author":"Truxova","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i29.3941","article-title":"Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns","volume":"25","author":"Jiraviriyakul","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v7.i11.338","article-title":"Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies","volume":"7","author":"Marks","year":"2015","journal-title":"World J Gastrointest Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jhepr.2019.06.003","article-title":"Immunobiology of cholangiocarcinoma","volume":"1","author":"Loeuillard","year":"2019","journal-title":"JHEP Rep: Innovation Hepatol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.982196","article-title":"Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma","volume":"13","author":"Pan","year":"2022","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02222-z","article-title":"Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated listeria monocytogenes in hepatobiliary cancers","volume":"41","author":"Hochnadel","year":"2022","journal-title":"Oncogene"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0048","article-title":"Exploring the role of oncolytic viruses in hepatobiliary cancers","volume":"10","author":"Tenneti","year":"2018","journal-title":"Immunotherapy"},{"key":"B121","article-title":"E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer","volume":"63","author":"Fukuda","year":"2003","journal-title":"Cancer Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3390\/cancers12051070","article-title":"Novel oncolytic virus armed with cancer suicide gene and normal vasculogenic gene for improved anti-tumor activity","volume":"12","author":"Jeong","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2015.60","article-title":"Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma","volume":"22","author":"Pugalenthi","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0474-1","article-title":"Clinical implications of cytotoxic T lymphocyte antigen-4 expression on tumor cells and tumor-infiltrating lymphocytes in extrahepatic bile duct cancer patients undergoing surgery plus adjuvant chemoradiotherapy","volume":"12","author":"Lim","year":"2017","journal-title":"Target Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12511","article-title":"The PD-1\/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma","volume":"67","author":"Sato","year":"2017","journal-title":"Pathol Int"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000497","article-title":"New emerging targets in cancer immunotherapy: the role of TIM3","volume":"4","author":"Friedlaender","year":"2019","journal-title":"ESMO Open"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3390\/cancers11081213","article-title":"LAG3: The biological processes that motivate targeting this immune checkpoint molecule in human cancer","volume":"11","author":"Solinas","year":"2019","journal-title":"Cancers"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00274","article-title":"IDO targeting in sarcoma: Biological and clinical implications","volume":"11","author":"Nafia","year":"2020","journal-title":"Front Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5101-y","article-title":"Program death 1 immune checkpoint and tumor microenvironment: Implications for patients with intrahepatic cholangiocarcinoma","volume":"23","author":"Gani","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.7150\/thno.36276","article-title":"Distinct PD-L1\/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors","volume":"9","author":"Lu","year":"2019","journal-title":"Theranostics"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"B132","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40425-019-0554-8","article-title":"HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1","volume":"7","author":"Jing","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B133","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/cco.2019.12.10","article-title":"Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma)","volume":"9","author":"Jakubowski","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hep.31410","article-title":"The tumor microenvironment in cholangiocarcinoma progression","author":"Fabris","year":"2021","journal-title":"Hepatology"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J Hepatol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15602","article-title":"PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma","volume":"8","author":"Fontugne","year":"2017","journal-title":"Oncotarget"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/jcm9061769","article-title":"Efficacy and safety of pembrolizumab for Gemcitabine\/Cisplatin-refractory biliary tract cancer: A multicenter retrospective study","volume":"9","author":"Lee","year":"2020","journal-title":"J Clin Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05787-0","article-title":"Expression of programmed death ligand 1 is associated with the prognosis of intrahepatic cholangiocarcinoma","volume":"65","author":"Dong","year":"2020","journal-title":"Dig Dis Sci"},{"key":"B139","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40425-016-0178-1","article-title":"Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation","volume":"4","author":"Masucci","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3390\/cancers14071748","article-title":"Evolving role of immunotherapy in advanced biliary tract cancers","volume":"14","author":"Kang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605465","article-title":"Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses","volume":"102","author":"Liu","year":"2010","journal-title":"Br J Cancer"},{"key":"B143","article-title":"Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy","volume":"34","author":"Koido","year":"2014","journal-title":"Anticancer Res"},{"key":"B144","doi-asserted-by":"publisher","first-page":"106006","DOI":"10.1016\/j.intimp.2019.106006","article-title":"Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells","volume":"78","author":"Sawasdee","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1408744","article-title":"Combination therapy with PD-1\/PD-L1 blockade: An overview of ongoing clinical trials","volume":"7","author":"Johnson","year":"2018","journal-title":"Oncoimmunology"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.3390\/cancers14071789","article-title":"Targeted therapies for perihilar cholangiocarcinoma","volume":"14","author":"Gray","year":"2022","journal-title":"Cancers"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","author":"Oh","year":"2022","journal-title":"J Clin Onc"},{"key":"B148","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.3390\/cancers14092137","article-title":"Changing landscape of systemic therapy in biliary tract cancer","volume":"14","author":"Woods","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2022.2055548","article-title":"Combination systemic therapies with immune checkpoint inhibitors in biliary tract cancer: effective but not enough","volume":"16","author":"Rizzo","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic radiation therapy augments antigen-specific PD-1-Mediated antitumor immune responses via cross-presentation of tumor antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B151","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3322\/caac.21358","article-title":"Radiotherapy combination opportunities leveraging immunity for the next oncology practice","volume":"67","author":"Herrera","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12658","article-title":"Radiotherapy-immunotherapy combinations - perspectives and challenges","volume":"14","author":"Mondini","year":"2020","journal-title":"Mol Oncol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"4304817","DOI":"10.1155\/2019\/4304817","article-title":"The combination of stereotactic body radiation therapy and immunotherapy in primary liver tumors","volume":"2019","author":"Kreidieh","year":"2019","journal-title":"J Oncol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s40425-019-0692-z","article-title":"Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade","volume":"7","author":"Liu","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00368","article-title":"Anti-PD-1 immunotherapy and radiotherapy for stage IV intrahepatic cholangiocarcinoma: A case report","volume":"7","author":"Liu","year":"2020","journal-title":"Front Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2020.1834792","article-title":"Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases","volume":"22","author":"Zhao","year":"2021","journal-title":"Cancer Biol Ther"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-41008-7_9","article-title":"Immunotherapy and radiation","volume":"1244","author":"Colbert","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0083","article-title":"Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities","volume":"3","author":"Cairns","year":"2013","journal-title":"Cancer Discovery"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: The phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"B162","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3390\/cells9030688","article-title":"New and emerging systemic therapeutic options for advanced cholangiocarcinoma","volume":"9","author":"Massironi","year":"2020","journal-title":"Cells"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br J Cancer"},{"key":"B164","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3350\/cmh.2021.0287","article-title":"Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance","volume":"28","author":"Komuta","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017832","article-title":"Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B169","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"B170","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00293","article-title":"Inflammation and progression of cholangiocarcinoma: Role of angiogenic and lymphangiogenic mechanisms","volume":"6","author":"Roy","year":"2019","journal-title":"Front Med"},{"key":"B172","doi-asserted-by":"publisher","first-page":"17588359211036544","DOI":"10.1177\/17588359211036544","article-title":"IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer","volume":"13","author":"Hack","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2018.00309","article-title":"Emergence of intrahepatic cholangiocarcinoma: How high-throughput technologies expedite the solutions for a rare cancer type","volume":"9","author":"Shiao","year":"2018","journal-title":"Front Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1037945\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T05:54:51Z","timestamp":1681710891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1037945\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":174,"alternative-id":["10.3389\/fimmu.2023.1037945"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1037945","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"article-number":"1037945"}}